Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpower150: Atezolizumab in metastatic non-squamous NSCLC
NCT02366143Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2015
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Roche. Primary endpoints: Progression Free Survival at 29 months and Overall Survival at 53 months. Started Mar 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02366143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366143.